RxDoctor Payments Data

Kanika White, NP

Nurse Practitioner · Columbus, GANPI 1891134672

Payments from drug & device makers

$6,615in general payments, 2019–2025

Across 354 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$963
  • Novo Nordisk$901
  • Lilly USA, LLC$840
  • Bayer$807
  • Boehringer Ingelheim$581
  • GSK$430
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,615 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$50,138
Medicare patients
430
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$37,758
EliquisApixaban23$15,507
XareltoRivaroxaban11$12,702
VascepaIcosapent Ethyl13$7,948
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,936
Synjardy XrEmpagliflozin/Metformin Hcl11$3,264
ValacyclovirValacyclovir Hcl20$1,393
Albuterol Sulfate HfaAlbuterol Sulfate37$996
Atorvastatin Calcium105$794
Alendronate Sodium80$793
Diclofenac Sodium24$743
Pantoprazole Sodium67$661
Gabapentin34$632
Fluticasone Propionate23$631
Losartan Potassium62$616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$901$37,75821 claims
PfizerEliquis$113$15,50723 claims
Johnson & JohnsonXarelto$80$12,70211 claims
GSKTrelegy Ellipta$430$6,93611 claims
Boehringer IngelheimSynjardy Xr$581$3,26411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →